A study of low- and middle-income working American adults under 65 finds that those with volatile working hours, incomes and employment are much less likely to have access to employer-sponsored insurance, and that most of those with volatile hours have some weeks below the 20 hours of work that Medicaid work requirements will require in 2027.

A new analysis published in NEJM Catalyst Innovations in Care Delivery finds that the standard response to growing specialist wait times, hiring more physicians, is unlikely to solve the problem on its own, and may even worsen it.

In a study analyzing nearly 3,000 brain MRI exams, researchers found that living in highly disadvantaged neighborhoods was associated with adverse brain health.

Michigan Medicine researchers found infection rates after cardiac surgery vary more than twofold across U.S. hospitals. Closing the gap could prevent 2,600 infections and save Medicare $441 million annually, while improving patient outcomes.

Project Remission, launched in partnership with Content With Purpose, is a digital film series exploring how evidence-based lifestyle medicine is transforming the standard of care for type 2 diabetes, shifting the focus from disease management to health restoration. The project features clinicians, health systems, educators, and industry leaders who are integrating the six pillars of lifestyle medicine into care to restore health, support clinician well-being, and strengthen healthcare systems.

Following the publication of its latest study in Nature Biotechnology, Insilico Medicine founder and CEO Alex Zhavoronkov, Ph.D., took the stage at Sorbonne University during the Nature AI Conference on Redefining Healthcare in the Age of AI to deliver a detailed presentation of the breakthrough findings.

Addressing an audience of global research leaders, clinical investigators, and biopharma innovators, Zhavoronkov detailed how the company’s AI-driven novel drug candidate, rentosertib (ISM001-055), achieved a unanimous reversal of biological age across six independent proteomic aging clocks in a Phase IIa clinical trial.